Posted on June 20, 2021 by Sitemaster
Back in 1989, the SWOG 8494 trial first showed that adding an antiandrogen (flutamide) to bilateral medical orchiectomy with an LHRH agonist (leuprolide acetate) extended median overall survival (OS) by 7 months in newly diagnosed men with metastatic, hormone-sensitive prostate cancer (mHSPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation, hormone-sensitive, metastatic, mHSPC, overall, survival, SWOG 1216 | 1 Comment »
Posted on February 3, 2020 by Sitemaster
According to a media release issued by Bayer a couple of days ago, the combination of androgen deprivation therapy (ADT) + darolutamide (Nubeqa) extends overall survival “significantly” in men with non-metastatic, castration-resistant prostate cancer (nmCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, darolutamide, nmCRPC, non-metastatic, overall, survival | 2 Comments »
Posted on June 2, 2019 by Sitemaster
The randomized, double-blind, Phase III ENZAMET trial was designed to investigate whether the combination of enzalutamide + standard androgen suppression had superior outcomes than a non-steroidal antiandrogen + standard androgen suppression in men with metastatic, hormone-sensitive prostate cancer (mHSPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: antiandrogen, enzalutamide, ENZAMET, hormone-sensitive, metastatic, mHSPC, non-steroidal, overall, survival | 15 Comments »
Posted on December 19, 2018 by Sitemaster
There has been regular discussion here and elsewhere about the degree to which new forms of therapy have impacted patient survival since the original approval of docetaxel for treatment of metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: benefit, castration-resistant, Dana-Farber, metastatic, overall, survival | 11 Comments »
Posted on November 16, 2017 by Sitemaster
A newly published study entitled “Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study” is important … but needs to be interpreted with a significant degree of caution. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: cancer-specific, metastatic, mortality, overall, survival, Treatment | 3 Comments »
Posted on October 13, 2017 by Sitemaster
A newly published study in the journal Urology (“the Gold journal”) has reported data on risk of death from prostate cancer and other causes among > 3,000 contemporary patients diagnosed with non-metastatic prostate cancer in 2004-2005. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: cancer-specific, mortality, Norway, overall, rate, risk | 4 Comments »
Posted on August 11, 2017 by Sitemaster
As many readers will have realized, the major regulatory authorities started, some time ago, to accept prostate cancer progression-free survival of differing types as a surrogate for overall survival in the approval of some drugs for the treatment of prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: enpoint, metastasis-free, overall, surrogate, survival, trial | 2 Comments »
Posted on June 17, 2016 by Sitemaster
Finally, we may have the perfect paper that illustrates the critical difference between overall mortality rates and cancer-specific cancer rates among men with prostate cancer, and how affecting one may have no effect whatsoever on the other! … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: diet, mortality, nuts, overall, prostate cancer-specific, survival | 2 Comments »
Posted on February 22, 2016 by Sitemaster
Probably because of high level of research funding as a consequence of the Movember Foundation‘s initiatives, Australia is increasingly providing us with interesting data on the diagnosis, management, and outcomes of men with prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: Diagnosis, mortality, outcome, overall, prostate cancer-specific, PSA, risk | 105 Comments »
Posted on October 13, 2015 by Sitemaster
Yet another study involving a large number of patients (this one from Taiwan) has again concluded that men with prostate cancer who take statins are less likely to die within a definable time period than men with prostate cancer who are not taking statins. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: mortality, overall, risk, statin | 2 Comments »
Posted on September 10, 2015 by Sitemaster
A new article in the Scandinavian Journal of Urology provides us with some insight — from relatively recent data — into the survival times of men with metastatic, castration-resistant prostate cancer (mCRPC) after prior treatment with androgen deprivation therapy (ADT) but who either decline or do not receive any further form of life-prolonging therapy. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, mCRPC, metastatic, overall, survival, untreated | 3 Comments »
Posted on April 8, 2015 by Sitemaster
An open-access, full text article in the April issue of the Journal of Urology addresses long-standing questions about the impact of regular aspirin use on the long-term outcomes of men diagnosed with and treated for prostate cancer. … READ MORE
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: anti-inflammatory, aspirin, mortality, overall, prostate cancer-specific | 2 Comments »
Posted on July 1, 2013 by Sitemaster
The issue of how long a man who is newly diagnosed with localized prostate cancer is likely to live before he dies a natural death from other causes is a crucial element in the decision whether to undergo treatment (and how aggressive that treatment may need to be). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: mortality, non-prostate cancer-specific, outcome, overall, prostate cancer-specific, risk | 6 Comments »
Posted on March 18, 2013 by Sitemaster
According to a media release issued by the European Association of Urology on Saturday, just prior to the opening of their annual meeting in Milan, Italy, “Surgery is superior to radiotherapy in men with localized [prostate cancer].” This headline is not even justifiable based on the content of the media release. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: outcome, overall, prostate cancer-specific, radiation, risk, surgery, Sweden | 2 Comments »
Posted on February 12, 2013 by Sitemaster
A new article in European Urology suggests that the mean life expectancy for men participating in recent clinical trials and expanded access programs for new drugs for the treatment of chemotherapy-naive, castration-resistant prostate cancer (CRPC) — including metastatic and non-metastatic patients — is now just over 30 months. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, chemotherapy-naïve, overall, survival | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 